Great recognition to a fundamental discovery that reshaped modern #immunology. Congrats to the laureates!

However, imho the Nobel committee missed the chance to acknowledge an additional key contributor to the understanding of #Foxp3 and #Treg functionality

BioNTech and Bristol Myers Squibb @bristolmyerssquibb.bsky.social enter global strategic #partnership to advance BNT327 (PD-L1 x VEGF-A bispecific #antibody) & #oncology leadership

Excited to be attending the 25th #BioEquityEurope in Bruges! Looking forward to reconnecting with fellow investors and #biotech colleagues across the life sciences ecosystem.

Feel free to reach out if you'd like to connect during the event!

#venturecapital #lifesciences

Happy to announce the launch of Adaptam Therapeutics, a new #biotech company pioneering #cancer immunotherapies by disrupting the immunosuppressive #myeloid TME through glyco-immune checkpoints to treat solid tumors

I’m proud to be a founding member and to have led its incubation as Board Director

Fantastic evening supporting the first lecture organized by #CaixaResearchInstitute and catching up with many colleagues! It’s always inspiring to hear Gabi as he guides us through a ‘sweet’ path at the intersection of #glycobiology and #immunology with tremendous potential for human diseases.

The PCSK9-targeting epigenetic editor led to rapid and sustained 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates

The human PCSK9-targeting #epigenetic editor packaged into an #LNP was able to reduce circulating PCSK9 protein 98% for a year after a *single administration* in a human PCSK9 transgenic mouse 🤯

ctDNA analysis revealed that a single dose of CAR-M induced robust *but transient* anti-tumor activity in patients with HER2 3+ tumors. Encouraging early data from this FIH, the field should build upon it!

What will #Lilly and #Novo outlook be for 2025?

$CARM has undergone a strategic restructuring, focusing on in vivo CAR-M generation (relying on its ongoing collaboration w Moderna to exploit mRNA/LNPs) and shifting toward #fibrosis, #oncology and #autoimmunity

Are we facing a new gold standard for intermediate stage #HCC? Lenvatinib (multi TKI) + pembrolizumab, combined with transarterial chemoembolisation (TACE), outperforms TACE alone (SoC) in PFS in a global, randomized, double-blind Phase 3 trial.

www.thelancet.com/journals/lan...

Promising data in #IBD! Duvakitug, an anti-TL1A mAb, delivered positive Phase 2b results in moderate-to-severe ulcerative colitis and Crohn’s disease.

Co-developed by Teva and Sanofi, a Phase 3 trial led by Sanofi is expected to kick off in 2025.

ir.tevapharm.com/news-and-eve...

Delighted to have contributed to #CaixaImpulse Innovation one more edition, first delivering my annual #venturecapital 101 lecture and today participating in the investor's round table at the closing ceremony. It's always a blast to ignite the #entrepreneurial mindset in driven researchers!

$PSTX platform includes non-viral capabilities to design, develop and manufacture #allogeneic, T stem cell memory-rich #CART therapies. The acquisition will establish a new capability for Roche in allogeneic #celltherapy, with CAR-T programs in hemato malignancies, solid tumors & autoimmune diseases

Kate’s 'Directed Evolution of #AAV Capsid Leveraging In Vivo Expression of Transgene RNA' (DELIVER) platform has been used to evolve a novel class of liver de-targeted muscle-tropic capsids, which transduce skeletal muscle & cardiac tissue with potency & selectivity in vivo, while avoiding the liver

In its R&D day, BioNTech $BNTX shared its upcoming plans for BNT327 in lung, breast, GI and other tumor types, with short term readouts in SCLC and #TNBC, and in combo studies with a variety of different modalities (including #ADC and mRNA #vaccines)

BioNTech and Biotheus were already co-developing BNT327/PM8002 under a strategic #partnership established in Nov 2023 (over $1B). $BNTX is transitioning to a multi-product commercial #oncology company

Keytruda accounted for $25B of Merck’s $60B in revenue last year, when it became the world’s best-selling #medicine. But there is still room for improvement, as most patients don’t durably respond to ICBs. Keytruda is facing patent cliff in 2028, and $MRK will be pressed to replace lost revenues